160 related articles for article (PubMed ID: 8709619)
1. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
Rowley PT; Keng PC; Kosciolek BA
Leuk Res; 1996 Jun; 20(6):473-80. PubMed ID: 8709619
[TBL] [Abstract][Full Text] [Related]
2. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
3. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
4. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
6. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
[TBL] [Abstract][Full Text] [Related]
7. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
8. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
9. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.
Rowley PT; Kosciolek BA; Kool ET
Mol Med; 1999 Oct; 5(10):693-700. PubMed ID: 10602778
[TBL] [Abstract][Full Text] [Related]
10. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
11. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
Thomas M; Kosciolek B; Wang N; Rowley P
Leuk Res; 1994 Jun; 18(6):401-8. PubMed ID: 8207957
[TBL] [Abstract][Full Text] [Related]
12. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
Smetsers TF; Linders EH; van de Locht LT; de Witte TM; Mensink EJ
Br J Haematol; 1997 Feb; 96(2):377-81. PubMed ID: 9029029
[TBL] [Abstract][Full Text] [Related]
13. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
O'Brien SG; Kirkland MA; Melo JV; Rao MH; Davidson RJ; McDonald C; Goldman JM
Leukemia; 1994 Dec; 8(12):2156-62. PubMed ID: 7808004
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
15. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
[TBL] [Abstract][Full Text] [Related]
16. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
Chasty R; Whetton A; Lucas G
Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
19. Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells.
Hoshiko T; Kubota Y; Akisawa T; Watanabe T; Tanigawara K; Yano J; Kimura S
Invest New Drugs; 2020 Aug; 38(4):1012-1019. PubMed ID: 31650445
[TBL] [Abstract][Full Text] [Related]
20. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]